Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Noah K. Schomburg"'
Autor:
Jacob E. Larson, P. Brian Hardy, Noah K. Schomburg, Xiaodong Wang, Dmitri Kireev, Kent L. Rossman, Kenneth H. Pearce
Publikováno v:
SLAS Discovery, Vol 28, Iss 1, Pp 39-47 (2023)
Mutations in the small GTPase protein KRAS are one of the leading drivers of cancers including lung, pancreatic, and colorectal, as well as a group of developmental disorders termed “Rasopathies”. Recent breakthroughs in the development of mutant
Externí odkaz:
https://doaj.org/article/d51a173c0d3d402c8c67f70bb132faf6
Publikováno v:
Cell Communication and Signaling, Vol 18, Iss 1, Pp 1-7 (2020)
Abstract Phase three clinical trial evidence suggests that colorectal cancers with the KRAS G13D mutation may benefit from EGFR inhibitors, like cetuximab, in contrast to the other most common KRAS mutations. A mechanism to explain why this mutation
Externí odkaz:
https://doaj.org/article/7cc8b0a5e5f043cda4dd6ca790b86978
Autor:
Jacob E. Larson, P. Brian Hardy, Noah K. Schomburg, Xiaodong Wang, Dmitri Kireev, Kent L. Rossman, Kenneth H. Pearce
Publikováno v:
SLAS discovery : advancing life sciences RD.
Mutations in the small GTPase protein KRAS are one of the leading drivers of cancers including lung, pancreatic, and colorectal, as well as a group of developmental disorders termed "Rasopathies". Recent breakthroughs in the development of mutant-spe
Publikováno v:
Cell Communication and Signaling : CCS
Cell Communication and Signaling, Vol 18, Iss 1, Pp 1-7 (2020)
Cell Communication and Signaling, Vol 18, Iss 1, Pp 1-7 (2020)
Phase three clinical trial evidence suggests that colorectal cancers with the KRAS G13D mutation may benefit from EGFR inhibitors, like cetuximab, in contrast to the other most common KRAS mutations. A mechanism to explain why this mutation behaves d